OPKO Health (OPK) to Release Quarterly Earnings on Wednesday

OPKO Health (NASDAQ:OPK) will issue its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). The business had revenue of $173.70 million for the quarter, compared to analyst estimates of $182.99 million. OPKO Health had a negative return on equity of 17.89% and a negative net margin of 31.44%. The business’s revenue was down 26.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.02) earnings per share. On average, analysts expect OPKO Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OPKO Health Trading Up 2.7 %

NASDAQ:OPK traded up $0.04 on Tuesday, hitting $1.35. The stock had a trading volume of 834,372 shares, compared to its average volume of 8,653,972. OPKO Health has a 1-year low of $0.85 and a 1-year high of $2.03. The company has a fifty day moving average price of $1.34 and a two-hundred day moving average price of $1.20. The company has a quick ratio of 1.62, a current ratio of 1.91 and a debt-to-equity ratio of 0.27. The stock has a market cap of $937.45 million, a price-to-earnings ratio of -3.74 and a beta of 1.65.

Analyst Ratings Changes

Several analysts have recently commented on OPK shares. StockNews.com upgraded shares of OPKO Health to a “sell” rating in a research note on Saturday, July 27th. Piper Sandler reduced their price objective on shares of OPKO Health from $5.00 to $3.00 and set an “overweight” rating for the company in a research note on Thursday, July 18th. Finally, HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a report on Wednesday, May 8th.

Insider Activity at OPKO Health

In other news, major shareholder Opko Health, Inc. sold 88,839 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $33.50, for a total value of $2,976,106.50. Following the completion of the transaction, the insider now directly owns 2,984,564 shares in the company, valued at $99,982,894. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other OPKO Health news, CEO Phillip Md Et Al Frost bought 100,000 shares of the company’s stock in a transaction on Thursday, May 23rd. The shares were bought at an average cost of $1.27 per share, with a total value of $127,000.00. Following the completion of the acquisition, the chief executive officer now owns 211,232,222 shares of the company’s stock, valued at $268,264,921.94. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Opko Health, Inc. sold 88,839 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $33.50, for a total transaction of $2,976,106.50. Following the sale, the insider now directly owns 2,984,564 shares in the company, valued at $99,982,894. The disclosure for this sale can be found here. Over the last three months, insiders sold 474,039 shares of company stock worth $15,239,114. 47.26% of the stock is owned by company insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.